Long-Term Effect of TIMP3 Gene Expression on Thyroid Cancer: A Cure Model Analysis

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Thyroid cancer is the most common endocrine malignancy.
• Tissue inhibitor of metalloproteinase-3 (TIMP3) can inhibit key processes in thyroid cancer, including angiogenesis, invasion, and metastasis.
• Understanding the role of TIMP3 in thyroid cancer prognosis is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the long-term impact of TIMP3 gene expression on the survival rate and cure probability of thyroid cancer patients.
• To identify TIMP3 as a potential prognostic biomarker for thyroid cancer.
• To explore the association between TIMP3 expression and long-term recovery in thyroid cancer.

Main Methods:

• A historical cohort study involving 507 thyroid cancer patients and 59 control samples from the TCGA database.
• Kaplan-Meier curves and log-rank tests were used for survival analysis.
• Weibull mixture cure models were employed to assess the relationship between TIMP3 expression and cure status.

Main Results:

• Patients with thyroid cancer exhibited significantly lower TIMP3 expression compared to normal tissue (p<0.001).
• After a median follow-up of 2,000 days, 78% of patients achieved cure, with higher TIMP3 expression correlating with an increased odds of cure (approximately 2.3 times greater).
• The Weibull mixture cure model proved superior to the non-mixture model in this analysis.

Conclusions:

• TIMP3 expression demonstrates a protective effect on the cure probability of thyroid cancer patients, particularly for long-term outcomes.
• TIMP3 does not appear to influence short-term survival rates in thyroid cancer.
• Targeting TIMP3 presents a promising therapeutic strategy and TIMP3 may serve as a valuable prognostic biomarker for thyroid cancer.